Prognostic Analysis of the IDH1 G105G (rs11554137) SNP in IDH-Wildtype Glioblastoma
Authors:
- Ayoub SaaidASAyoub Saaid
- Matteo MonticelliMMMatteo Monticelli
- Alessia Andrea RicciARAlessia Andrea Ricci
- Giulia OrlandoGOGiulia Orlando
- Cristina BottaCBCristina Botta
- Pietro ZeppaPZPietro Zeppa
- Andrea BianconiABAndrea Bianconi
- Simona Osella-AbateSOSimona Osella-Abate
- Francesco BrunoFBFrancesco Bruno
- Alessia PellerinoAlessia Pellerino
- Roberta RudàRoberta Rudà
- Paola CassoniPCPaola Cassoni
Open Access
Abstract
The G105G SNP (rs11554137) in the IDH1 gene is observed in about 10–15% of patients with a diffuse glioma. Data regarding its impact on gliomas are poor and partially conflicting, possibly due to the evolving classification of CNS tumors. The aim of this study was to investigate the G105G SNP prognostic significance in a homogenous cohort of IDH-wildtype glioblastomas, in agreement with the 2021 WHO classification. The study analyzed 211 patients by collecting several clinico-pathological and molecular characteristics, including the age, lesion localization, number of involved lobes, type of surgical treatment, disease outcome and MGMT promoter methylation status. PFS and DSS curves were plotted according to the Kaplan–Meier method and statistical analyses were performed using parametric and non-parametric tests. A total of 32 patients out of 211 (15.2%) were found to be G105G SNP carriers. No significant impact of the IDH1 G105G SNP on patients’ outcomes was observed in terms of PFS and DSS, while MGMT promoter methylation and gross total resection resulted as key prognostic factors in our cohort as expected. No prognostic impact of the IDH1 G105G SNP was detected in this strict cohort of IDH-wildtype glioblastomas. Analysis of larger cohorts is warranted to address the sample size limitations.Keywords
Funding Information
- NIH (DK98717, AG47326)
- Instituto Politécnico Nacional (SIP-20220789)
This publication has 18 references indexed in Scilit:
- Correlation Between Isocitrate Dehydrogenase Gene Aberrations and Prognosis of Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-AnalysisClinical Cancer Research, 2017
- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summaryActa Neuropathologica, 2016
- IDH mutations in cancer and progress toward development of targeted therapeuticsAnnals of Oncology, 2016
- Prognostic impact of the isocitrate dehydrogenase 1 single-nucleotide polymorphism rs11554137 in malignant gliomasCancer, 2012
- Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children's Oncology Group and SWOGBlood, 2011
- Impact of IDH1 R132 Mutations and an IDH1 Single Nucleotide Polymorphism in Cytogenetically Normal Acute Myeloid Leukemia: SNP rs11554137 Is an Adverse Prognostic FactorJournal of Clinical Oncology, 2010
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working GroupJournal of Clinical Oncology, 2010
- Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapyBritish Journal of Cancer, 2009
- A "Silent" Polymorphism in the MDR 1 Gene Changes Substrate SpecificityScience, 2007
- Predictive Identification of Exonic Splicing Enhancers in Human GenesScience, 2002